Janssen’s latest move against Amgen highlights shifting pharma patent strategies
J&J subsidiary makes innovative use of IP acquired in $6.5 billion Momenta acquisition
J&J subsidiary makes innovative use of IP acquired in $6.5 billion Momenta acquisition
The EBA has not laid out clear rules about when post-filed evidence can be used to demonstrate technical effect
What are the rights of public healthcare providers and companies seeking damages in the United Kingdom, the Netherlands, France and Norway?
19 October 2022
Forum considering whether and when post-filed evidence can be relied upon for purposes of plausibility
18 October 2022
Here’s a look at the data about the rights’ holders and dollar sums behind the 31 patent damages awards from 1 July to 30 September
17 October 2022
The move is latest setback for the patentee in its dramatic written description dispute
17 October 2022
The European Commission has preliminarily found that the Israeli company has broken antitrust rules
11 October 2022
Docket Navigator shows that Amgen’s in-house legal team appeared on 78 of the 85 patent assertions in US district court since 2008
10 October 2022
The past two weeks have seen a flurry of patent-related activity at the US Supreme Court
07 October 2022
The Supreme Court's request for Solicitor General input increases the chances of a hearing on skinny-label controversies
06 October 2022
Ravgen is pursuing several large diagnostics companies in patent enforcement drive
04 October 2022
Following the firm’s recent $115 million investment, Sagard Healthcare Royalty Partners’ Ali Alagheband says a flurry of activity is underway in the market
03 October 2022
Unlock unlimited access to all IAM content